Kombination aus Immunmodulator und Aktivierter Treg zur Behandlung Autoimmuner und Autoinflammatorischer Erkrankungen
EP4806433
16. September 2026
Anmelder: ActiTrexx GmbH 🇩🇪
Details
- Veröffentlichungs-Nr.
- EP4806433
- Anmeldetag
- 14. März 2025
- Veröffentlichung
- 16. September 2026
- Rechtsraum
- EP
Abstract
The present invention relates to an immunologically effective combination and a pharmaceutical composition, comprising at least one immunomodulatory agent and a regulatory T cell preparation for use in the prevention or treatment of an autoinflammatory or autoimmune disease. The invention also relates to the use of an immunologically effective combination for the manufacturing of a medicament that promotes and restores immune tolerance in a human or animal subject.
Anmelder
- Firma
- ActiTrexx GmbH
- Land
- 🇩🇪 Deutschland